ALNYLAM PHARMACEUTICALS Reports Q2 FY2023 Earnings Results on August 3 2023

🌥️Earnings Overview

Alnylam Pharmaceuticals ($NASDAQ:ALNY) reported their financial results for the second quarter of the fiscal year 2023 (ending on June 30 2023) on August 3 2023. Their total revenue for the quarter was USD 318.8 million, a 41.8% increase compared to the same period in the previous year. Their net income, however, was USD -276.0 million, a decrease from the -277.4 million reported in the same quarter of the prior year.

Share Price

The stock opened the day at $182.1 and closed the day at $190.1, representing a 1.7% increase from the last closing price of $187.0. ALNYLAM PHARMACEUTICALS also announced that it had received approval from the US Food and Drug Administration (FDA) for its new drug, Patisiran, which is used to treat a rare disease known as transthyretin amyloidosis. This approval has been well-received by investors, leading to the stock’s surge on Thursday. Overall, ALNYLAM PHARMACEUTICALS had a positive earnings report for Q2 FY2023, with their stock closing at $190.1 at the end of the day. This is a positive sign for the company and its investors going forward. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Alnylam Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Alnylam Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Alnylam Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Alnylam Pharmaceuticals are shown below. More…

Analysis

At GoodWhale, we analyze ALNYLAM PHARMACEUTICALS‘s fundamentals to give investors the most comprehensive view of the company. According to our Star Chart, ALNYLAM PHARMACEUTICALS is strong in growth, medium in asset and weak in dividend, profitability. Our health score for ALNYLAM PHARMACEUTICALS is 2/10, indicating that the company is less likely to sustain future operations in times of crisis due to its weak cashflows and debt. We also classify ALNYLAM PHARMACEUTICALS as a ‘Cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high growth investments with above-average risk should consider investing in ALNYLAM PHARMACEUTICALS. Given its low health score, investors should approach such investments cautiously and ensure that they diversify their portfolio and limit their exposure to such companies. More…

Peers

The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s competitors include Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc, and Novartis AG.

– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)

As of 2022, Regeneron Pharmaceuticals Inc has a market cap of 79.02B and a Return on Equity of 19.7%. The company is a biotech company that focuses on the discovery, development, and commercialization of medicines for the treatment of serious medical conditions.

– Intellia Therapeutics Inc ($NASDAQ:NTLA)

Intellia Therapeutics is a gene-editing company that focuses on developing therapeutics to treat serious diseases. The company has a market cap of $3.96 billion as of 2022 and a return on equity of -26.91%. Intellia’s gene-editing technology is based on CRISPR-Cas9, which is a naturally occurring bacterial system that can be used to target and edit specific genes. The company’s pipelines include programs for sickle cell disease, beta thalassemia, Huntington’s disease, and transthyretin amyloidosis.

– Novartis AG ($LTS:0QM7)

Novartis AG is a global pharmaceutical company with a market cap of 169.13B as of 2022. It has a Return on Equity of 24.65%. The company focuses on the discovery, development, and commercialization of healthcare products. Novartis’s products include over-the-counter and prescription drugs, vaccines, and diagnostic tools. The company has operations in over 140 countries and its products are sold in 180 countries.

Summary

Investors in Alnylam Pharmaceuticals have seen an impressive 41.8% increase in total revenue for the second quarter of FY2023, coming in at USD 318.8 million. However, the net income for the quarter was reported at a loss of USD 276.0 million, a decrease from the prior year. Despite the net loss, investors may be encouraged by the strong revenue growth, which could indicate a promising future for Alnylam. With continued focus on its pipeline and innovative treatments, Alnylam could be a good long-term investment.